Drugs & Targets FDA permits expanded access for investigational pancreatic cancer drug daraxonrasib May 08, 2026Vol.52 No.18By Claire Marie Porter
Drugs & Targets FDA approves Jakafi XR tablets for myelofibrosis, polycythemia vera, and graft-versus-host disease May 08, 2026Vol.52 No.18
Podcast Reforms pending at USPSTF, plus, FDA rejects promising melanoma drug for the second time May 06, 2026
Regulatory News FDA’s second rejection of Replimune’s melanoma treatment stirs worry among oncologists, patients“Patients are owed another review.” May 01, 2026Vol.52 No.17By Sara Willa Ernst
Drugs & Targets ODAC recommends against approval of camizestrant NDA, gives a nod to sNDA for capivasertib May 01, 2026Vol.52 No.17By Jacquelyn Cobb
Drugs & Targets FDA grants priority review for Ziihera in first-line HER2+ GEA May 01, 2026Vol.52 No.17
Cancer Policy One year of reducing animal testing in drug development April 24, 2026Vol.52 No.16By Claire Marie Porter
Cancer Policy FDA and CMS announce RAPID coverage pathway aimed at accelerating patient access to some Breakthrough medical devices April 24, 2026Vol.52 No.16
Drugs & Targets FDA grants Fast Track designation for lunresertib + zedoresertib for genomic-defined platinum-resistant ovarian cancer April 24, 2026Vol.52 No.16
